Showing 3251-3260 of 3540 results for "".
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- New Patient Education Service from Vivacare Helps Medical Professionals Deliver Health Education at the Point of Carehttps://practicaldermatology.com/news/20140716-new_patient_education_service_from_vivacare_helps_medical_professionals_deliver_health_education_at_the_point_of_care/2459166/Vivacare, a leading provider of patient education services for physicians, today announced a major upgrade to its free, web-based service and the opportunity for physician assistants, nurse practitioners and other medical professionals to enroll. In just minutes, physicians and other medical pr
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scor
- MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind Systemhttps://practicaldermatology.com/news/20140715-mela_sciences_begins_insurance_reimbursement_process_with_application_for_new_cpt_code_for_the_melafind_system/2459170/MELA Sciences, Inc. (Nasdaq:MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection o
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Applicationhttps://practicaldermatology.com/news/20140711-kythera_biopharmaceuticals_announces_fda_acceptance_of_atx-101_new_drug_application/2459173/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficien
- PuraCap Pharmaceutical Introduces EpiCeram 225g Airless Pumphttps://practicaldermatology.com/news/20140711-puracap_pharmaceutical_introduces_epiceram_225g_airless_pump/2459174/PuraCap Pharmaceutical introduced the newest addition to the EpiCeram product line, the EpiCeram 225g Airless Pump. The airless pump gives patients more EpiCeram to treat any size area of atopi
- Ultherapy Decolletage Treatment Now FDA Clearedhttps://practicaldermatology.com/news/20140707-ultherapy_dcolletage_treatment_now_fda_cleared/2459179/The FDA cleared Ulthera, Inc.'s Ulthera System for the non-invasive treatment of the chest to improve lines and wrinkles of the décolleté. The Ultherapy Décolletage Treatment uses the system's signature imaging and micro-focued ultr
- Aclaris Therapeutics Announces Positive Results from Phase II study of Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/20140702-aclaris_therapeutics_announces_positive_results_from_phase_ii_study_of_seborrheic_keratosis_treatment/2459181/Aclaris Therapeutics, Inc. announced positive results from a Phase II clinical trial of the its lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK). The double-bl